Pfizer (PFE) Misses Q3 EPS by 9c; Reaffirms FY Outlook

Pfizer (NYSE: PFE) reported Q3 EPS of ($0.17), $0.09 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $13.2 billion versus the consensus estimate of $13.33 billion.

GUIDANCE:

Pfizer sees FY2023 EPS of $1.45-$1.65, versus the consensus of $1.50. Pfizer sees FY2023 revenue of $58-61 billion, versus the consensus of $55.37 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright
• Helix and Hornbeck complete all-stock merger, form new NYSE: HOS